What is NewLimit?
Founded in 2022, NewLimit operates at the intersection of advanced biotechnology and regenerative medicine. The company is dedicated to developing therapeutic solutions that address the underlying mechanisms of cellular aging. By focusing on the reprogramming of aged cells, NewLimit aims to mitigate age-related decline, positioning itself as a critical player in the emerging field of preemptive medicine. The firm's strategic approach combines rigorous scientific inquiry with a long-term vision for transforming how healthcare systems manage the aging process, moving beyond traditional symptom management toward fundamental biological restoration.
How much funding has NewLimit raised?
NewLimit has raised a total of $605M across 3 funding rounds:
Series A
$40M
Series B
$130M
Series C
$435M
Series A (2023): $40M with participation from Kleiner Perkins, Dimension Capital Management, and Founders Fund
Series B (2025): $130M led by Kleiner Perkins, Khosla Ventures, and The Human Capital Institute
Series C (2026): $435M supported by Founders Fund, Kleiner Perkins, Thrive Capital, Valor Equity Partners, Greenoaks, Quiet Capital, and Abstract
Key Investors in NewLimit
Kleiner Perkins
A premier venture capital firm that provides comprehensive operational support and capital to early and growth-stage companies across the healthcare and technology sectors.
Founders Fund
A high-conviction investment firm known for backing transformative, founder-led companies across diverse sectors including biotechnology and advanced software.
Thrive Capital
A New York-based venture capital firm that specializes in identifying and scaling high-impact internet and software-driven enterprises.
What's next for NewLimit?
With the successful closure of its latest financing round, NewLimit is well-positioned to accelerate its research and development pipeline. The company is expected to leverage this capital to expand its laboratory infrastructure, enhance its proprietary cellular reprogramming platforms, and advance its lead candidates toward clinical validation. As the firm transitions from early-stage discovery to more mature development phases, the focus will likely shift toward establishing strategic partnerships and navigating the regulatory landscape for novel longevity therapeutics. This trajectory suggests a sustained commitment to scaling its operational capabilities to meet the growing global demand for innovative healthspan-extending technologies.
See full NewLimit company page
